Safety and Effectiveness of Adalimumab in Patients With Ankylosing Spondylitis in Routine Clinical Practice
Phase of Trial: Phase IV
Latest Information Update: 11 Nov 2015
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Abbott Laboratories; AbbVie
- 10 Jun 2017 Biomarkers information updated
- 16 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Dec 2013 Planned end date changed from 1 Dec 2013 to 1 May 2014 as reported by ClinicalTrials.gov.